Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic added to cyclosporine and prednisone for first-line extensive chronic graft-versus-host disease
NL-OMON30458Phase 3Active, not recruiting
- Sponsor
- EBMT
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Cyclosporine A + prednisone + placebo with Cyclosporine A + prednisone + Myfortic (2 arms). Primary endpoint: Response rate at 12 months without secondary systemic therapy. Started Jan 2008; status: active, not recruiting.
02
Drugs
mycophenolate sodium
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NL-OMON30458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30458.